

Under the Paperwork Reduction Act of 1995, no person is required to respond to the collection of information unless it contains a valid OMB control number.

Substitute for form 14690/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/075,257
Filing Date	February 15, 2002
First Named Inventor	Yoram REITER
Art Unit	1644
Examiner Name	VANDERVEGT, FRANCOIS P

Sheet

1

8

3

Casey Docket Number 02/23338

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

For Japanese patient documents, the indication of the year⁵ or the reign of the Emperor must precede the serial number.

- Kind of document by the appropriate symbols as indicated on the document under V

Application is to place a check mark here if English language translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and sending the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /PV/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

MAY 01 2008

U.S. PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet	2	OF	3	Attorney Docket Number	02/23338
-------	---	----	---	------------------------	----------

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	8	Abastado et al. "Dimerization of Soluble Major Histocompatibility Complex-Peptide Complexes Is Sufficient for Activation of T Cell Hybridoma and Induction of Unresponsiveness", Journal of Experimental Medicine, P.439-447, 1995. Abstract. P.439, Col.2, P.440, Col.1, § 1.	
	9	Bousso et al. "Enrichment of Antigen-Specific T Lymphocytes by Panning on Immobilized MHC-Peptide Complexes", Immunology Letters, 59(2): 85-91, 1997. Abstract. P.86, Col.1.	
	10	Denkberg et al. "Recombinant Human Single-Chain MHC-Peptide Complexes Made From E. Coli by In Vitro Refolding: Functional Single-Chain MHC-Peptide Complexes and Tetramers With Tumor Associated Antigens", European Journal of Immunology, 30(12): 3522-3532, 2000. Abstract. P.3524, Col.1, § 2, From Bottom.	
	11	Garboczi et al. "HLA-A2-Peptide Complexes: Refolding and Crystallization of Molecules Expressed in Escherichia Coli and Complexed With Single Antigenic Peptides", Proc. Natl. Acad. Sci. USA, 89: 3429-3433, 1992. Abstract. P.3429, Col.1, § 1.	
	12	Kourilsky et al. "Immunological Issues in Vaccine Trials: T-Cell Responses", Preclinical and Clinical Development of New Vaccines, 95: 117-124, 1998.	
	13	Lee et al. "Functional Cell Surface Expression by A Recombinant Single-Chain Class I Major Histocompatibility Complex Molecule With A Cis-Active Beta 2-Microglobulin Domain", European Journal of Immunology, 24(11): 2633-2639, 1994.	
	14	Ogg et al. "HLA-Peptide Tetrameric Complexes", Current Opinion in Immunology, 10: 393-396, 1998.	
	15	Ojeu et al. "Dissociation of the Peptide-MHC Class I Complex Limits the Binding Rate of Exogenous Peptide", Journal of Immunology, 151(11): 6020-6026, 1993.	
	16	Parker et al. "Peptide Binding to HLA-A2 and HLA-B27 Isolated From Escherichia Coli", The Journal of Biological Chemistry, 267(8): 5451-5459, 1992.	
	17	Parker et al. "Sequence Motifs Important for Peptide Binding to the Human MHC Class I Molecule, HLA-A2", Journal of Immunology, 149(11): 3580-3587, 1992.	
Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14; this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /PV/



U.S. DEPARTMENT OF COMMERCE, U.S. PATENT AND TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

<i>Complete if Known</i>	
Application Number	10/075,257
Filing Date	February 15, 2002
First Named Inventor	Yoram REITER
Art Unit	1644
Examiner Name	VANDERVEGT, FRANCOIS P

Sheet 3 of 3 Attorney Docket Number 02/23338

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature	/F Pierre VanderVegt/	Date Considered	12/03/2008
-----------------------	-----------------------	--------------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number.

⁵ Kind of document by the appropriate symbols as indicated on the document under No.

6. Applicant is to place a check mark here if English language translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14; this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissions for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /PV/